A Study of LY3502970 in Healthy Overweight and Obese Participants
- Registration Number
- NCT05313802
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
- Participants with stable body weight for at least one month prior to randomization.
- Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
- Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
- Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LY3502970 (Dose Level 2) LY3502970 LY3502970 administered orally. LY3502970 (Dose Level 1) LY3502970 LY3502970 administered orally. LY3502970 (Dose Level 3) LY3502970 LY3502970 administered orally.
- Primary Outcome Measures
Name Time Method Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Predose up to 42 days A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 Predose up to 29 days postdose PK: AUC of LY3502970
PK: Maximum Observed Concentration (Cmax) of LY3502970 Predose up to 29 days postdose PK: Cmax of LY3502970
Pharmacodynamics (PD): Change From Baseline in Body Weight Predose through Day 28 PD: Change From Baseline in Body Weight
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 Predose up to 29 days postdose PK: Tmax of LY3502970
Trial Locations
- Locations (3)
ICON Early Phase Services
🇺🇸San Antonio, Texas, United States
Qps-Mra, Llc
🇺🇸Miami, Florida, United States
ICON Early Phase Services Lenexa Center
🇺🇸Lenexa, Kansas, United States